Malaria, Falciparum

• 

  Subject Areas on Research

  • A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance of Plasmodium falciparum Following Artemisinin Treatment. 
  • A comparison of anemia in hemoglobin C and normal hemoglobin A children with Plasmodium falciparum malaria. 
  • A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan. 
  • A cross-sectional survey of Plasmodium falciparum pfcrt mutant haplotypes in the Democratic Republic of Congo. 
  • A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19 kDa. 
  • A longitudinal cohort study of malaria exposure and changing serostatus in a malaria endemic area of rural Tanzania. 
  • A malaria vaccine for control: more progress. 
  • A microarray platform and novel SNP calling algorithm to evaluate Plasmodium falciparum field samples of low DNA quantity. 
  • A molecular marker for chloroquine-resistant falciparum malaria. 
  • A network to monitor antimalarial drug resistance: a plan for moving forward. 
  • A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. 
  • A set of microsatellite markers to differentiate Plasmodium falciparum progeny of four genetic crosses. 
  • A study of the TNF/LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults. 
  • A validated agent-based model to study the spatial and temporal heterogeneities of malaria incidence in the rainforest environment. 
  • Absence of Association Between Sickle Trait Hemoglobin and Placental Malaria Outcomes. 
  • Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. 
  • Adaptive evolution and fixation of drug-resistant Plasmodium falciparum genotypes in pregnancy-associated malaria: 9-year results from the QuEERPAM study. 
  • Age-related susceptibility to severe malaria associated with galectin-2 in highland Papuans. 
  • An ultrasensitive reverse transcription polymerase chain reaction assay to detect asymptomatic low-density Plasmodium falciparum and Plasmodium vivax infections in small volume blood samples. 
  • Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. 
  • Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. 
  • Antibody Profiling by Proteome Microarray with Multiplex Isotype Detection Reveals Overlap between Human and Aotus nancymaae Controlled Malaria Infections. 
  • Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. 
  • Antigen-specific B memory cell responses to Plasmodium falciparum malaria antigens and Schistosoma haematobium antigens in co-infected Malian children. 
  • Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. 
  • Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. 
  • Arginine, nitric oxide, carbon monoxide, and endothelial function in severe malaria. 
  • Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. 
  • Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot. 
  • Artemisinin resistance in Myanmar. 
  • Artemisinin resistance in Plasmodium falciparum malaria. 
  • Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model. 
  • Artemisinin-Resistant Plasmodium falciparum in Africa. 
  • Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. 
  • Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. 
  • Association of HLA alleles with Plasmodium falciparum severity in Malian children. 
  • Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. 
  • Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria. 
  • Asymptomatic Plasmodium falciparum malaria in pregnant women in the Chittagong Hill Districts of Bangladesh. 
  • Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. 
  • Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. 
  • Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. 
  • Blood mononuclear cell nitric oxide production and plasma cytokine levels in healthy gabonese children with prior mild or severe malaria. 
  • Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem. 
  • Cases from the Osler Medical Service at Johns Hopkins University. 
  • Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial. 
  • Changes in Malaria Epidemiology in Africa and New Challenges for Elimination. 
  • Changes in the levels of chemokines and cytokines in the placentas of women with Plasmodium falciparum malaria. 
  • Characterizing microclimate in urban malaria transmission settings: a case study from Chennai, India. 
  • Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. 
  • Chloroquine-resistant malaria. 
  • Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. 
  • Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. 
  • Combination therapy for malaria: mission accomplished? 
  • Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. 
  • Complexity of the msp2 locus and the severity of childhood malaria, in south-western Nigeria. 
  • Conservation of a novel vacuolar transporter in Plasmodium species and its central role in chloroquine resistance of P. falciparum. 
  • Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. 
  • Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered? 
  • Cryogenically preserved RBCs support gametocytogenesis of Plasmodium falciparum in vitro and gametogenesis in mosquitoes. 
  • Decreased circulating macrophage migration inhibitory factor (MIF) protein and blood mononuclear cell MIF transcripts in children with Plasmodium falciparum malaria. 
  • Decreased endothelial nitric oxide bioavailability, impaired microvascular function, and increased tissue oxygen consumption in children with falciparum malaria. 
  • Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. 
  • Designing malaria vaccines to circumvent antigen variability. 
  • Detection of Plasmodium falciparum in pregnancy by laser desorption mass spectrometry. 
  • Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. 
  • Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. 
  • Developmental allometry and paediatric malaria. 
  • Differential recognition of terminal extracellular Plasmodium falciparum VAR2CSA domains by sera from multigravid, malaria-exposed Malian women. 
  • Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria. 
  • Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. 
  • Dimethylarginines: endogenous inhibitors of nitric oxide synthesis in children with falciparum malaria. 
  • Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. 
  • Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. 
  • Effects of age and parasitemia on nitric oxide production/leukocyte nitric oxide synthase type 2 expression in asymptomatic, malaria-exposed children. 
  • Effects of concomitant Schistosoma haematobium infection on the serum cytokine levels elicited by acute Plasmodium falciparum malaria infection in Malian children. 
  • Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia. 
  • Elevated nitric oxide production in children with malarial anemia: hemozoin-induced nitric oxide synthase type 2 transcripts and nitric oxide in blood mononuclear cells. 
  • Erythrocyte CR1 expression level does not correlate with a HindIII restriction fragment length polymorphism in Africans; implications for studies on malaria susceptibility. 
  • Etiology of pediatric fever in western Kenya: a case-control study of falciparum malaria, respiratory viruses, and streptococcal pharyngitis. 
  • Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance. 
  • Expression of complement and toll-like receptor pathway genes is associated with malaria severity in Mali: a pilot case control study. 
  • Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. 
  • Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. 
  • Gametocytemia in Plasmodium vivax and Plasmodium falciparum infections. 
  • Genetic Evidence of Importation of Drug-Resistant Plasmodium falciparum to Guatemala from the Democratic Republic of the Congo. 
  • Genetic architecture of artemisinin-resistant Plasmodium falciparum. 
  • Genetic diversity of the msp-1 locus and symptomatic malaria in south-west Nigeria. 
  • Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar. 
  • Genomic epidemiology of artemisinin resistant malaria. 
  • HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. 
  • Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. 
  • Hemoglobin C Trait Provides Protection From Clinical Falciparum Malaria in Malian Children. 
  • Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. 
  • Hemoglobin E and Glucose-6-Phosphate Dehydrogenase Deficiency and Plasmodium falciparum Malaria in the Chittagong Hill Districts of Bangladesh. 
  • Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. 
  • High levels of Plasmodium falciparum rosetting in all clinical forms of severe malaria in African children. 
  • High numerical aperture Fourier ptychography: principle, implementation and characterization. 
  • Higher production of peripheral blood macrophage migration inhibitory factor in healthy children with a history of mild malaria relative to children with a history of severe malaria. 
  • Host iron status and iron supplementation mediate susceptibility to erythrocytic stage Plasmodium falciparum. 
  • Human antibody response to Anopheles gambiae saliva: an immuno-epidemiological biomarker to evaluate the efficacy of insecticide-treated nets in malaria vector control. 
  • Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. 
  • Impact of intermittent screening and treatment for malaria among school children in Kenya: a cluster randomised trial. 
  • Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. 
  • Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. 
  • Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. 
  • Impaired systemic tetrahydrobiopterin bioavailability and increased dihydrobiopterin in adult falciparum malaria: association with disease severity, impaired microvascular function and increased endothelial activation. 
  • Impaired systemic tetrahydrobiopterin bioavailability and increased oxidized biopterins in pediatric falciparum malaria: association with disease severity. 
  • Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. 
  • Increased Susceptibility to Plasmodium falciparum in Infants is associated with Low, not High, Placental Malaria Parasitemia. 
  • Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. 
  • Increased risk of low birth weight in women with placental malaria associated with P. falciparum VAR2CSA clade. 
  • Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. 
  • Independent lineages of highly sulfadoxine-resistant Plasmodium falciparum haplotypes, eastern Africa. 
  • Interaction between acute diarrhoea and falciparum malaria in Nigerian children. 
  • Interactions between a fungal entomopathogen and malaria parasites within a mosquito vector. 
  • Intermittent preventive malaria treatment in Tanzanian infants. 
  • Intermittent preventive treatment for malaria in infants: moving forward, cautiously. 
  • Intraleucocytic malaria pigment and clinical severity of malaria in children. 
  • Inverse relationship of plasma prostaglandin E2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria. 
  • Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. 
  • Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. 
  • Lack of an association between antibodies to Plasmodium falciparum glycosylphosphatidylinositols and malaria-associated placental changes in Cameroonian women with preterm and full-term deliveries. 
  • Lack of association between falciparum malaria parasitemia and acute diarrhea in Nigerian children. 
  • Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. 
  • Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. 
  • Liver-stage malaria parasites vulnerable to diverse chemical scaffolds. 
  • Longitudinal studies of Plasmodium falciparum malaria in pregnant women living in a rural Cameroonian village with high perennial transmission. 
  • Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali. 
  • Low interleukin-12 activity in severe Plasmodium falciparum malaria. 
  • Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence. 
  • Malaria hotspots drive hypoendemic transmission in the Chittagong Hill Districts of Bangladesh. 
  • Malaria transmission potential could be reduced with current and future climate change. 
  • Malaria: Resistance nailed. 
  • Malaria: a rising incidence in the United States. 
  • Mapping hypoendemic, seasonal malaria in rural Bandarban, Bangladesh: a prospective surveillance. 
  • Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum. 
  • Microclimate variables of the ambient environment deliver the actual estimates of the extrinsic incubation period of Plasmodium vivax and Plasmodium falciparum: a study from a malaria-endemic urban setting, Chennai in India. 
  • Minimal Impact by Antenatal Subpatent Plasmodium falciparum Infections on Delivery Outcomes in Malawian Women: A Cohort Study. 
  • Molecular Epidemiology of Blood-Borne Human Parasites in a Loa loa-, Mansonella perstans-, and Plasmodium falciparum-Endemic Region of Cameroon. 
  • Molecular approaches to the spreading problem of drug resistant malaria. 
  • Molecular assays for surveillance of antifolate-resistant malaria. 
  • Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. 
  • Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. 
  • Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. 
  • Monitoring and deterring drug-resistant malaria in the era of combination therapy. 
  • Monitoring antimalarial drug resistance: making the most of the tools at hand. 
  • Monocyte polarization in children with falciparum malaria: relationship to nitric oxide insufficiency and disease severity. 
  • More on 'the efficacy of antifolate antimalarial combinations in Africa'. 
  • Multicenter Pivotal Clinical Trial of Urine Malaria Test for Rapid Diagnosis of Plasmodium falciparum Malaria. 
  • Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. 
  • Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens. 
  • Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. 
  • New var reconstruction algorithm exposes high var sequence diversity in a single geographic location in Mali. 
  • Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. 
  • Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria. 
  • No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. 
  • Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection. 
  • Ordered accumulation of mutations conferring resistance to sulfadoxine-pyrimethamine in the Plasmodium falciparum parasite. 
  • Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. 
  • Overlap Extension Barcoding for the Next Generation Sequencing and Genotyping of Plasmodium falciparum in Individual Patients in Western Kenya. 
  • Parasite prevalence: a static measure of dynamic infections. 
  • Permethrin-impregnated bed nets for malaria control in northern Guatemala: epidemiologic impact and community acceptance. 
  • Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi. 
  • Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. 
  • Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. 
  • Plasma interleukin-12 in malaria-tolerant papua new guineans: inverse correlation with Plasmodium falciparum parasitemia and peripheral blood mononuclear cell nitric oxide synthase activity. 
  • Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. 
  • Plasmodium falciparum field isolates from areas of repeated emergence of drug resistant malaria show no evidence of hypermutator phenotype. 
  • Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. 
  • Plasmodium falciparum malaria in south-west Nigerian children: is the polymorphism of ICAM-1 and E-selectin genes contributing to the clinical severity of malaria? 
  • Plasmodium falciparum parasitaemia in the first half of pregnancy, uterine and umbilical artery blood flow, and foetal growth: a longitudinal Doppler ultrasound study. 
  • Plasmodium falciparum sulfadoxine resistance is geographically and genetically clustered within the DR Congo. 
  • Plasmodium falciparum-infected erythrocytes adhere both in the intervillous space and on the villous surface of human placenta by binding to the low-sulfated chondroitin sulfate proteoglycan receptor. 
  • Plasmodium vivax Infections over 3 Years in Duffy Blood Group Negative Malians in Bandiagara, Mali. 
  • Platelet-mediated clumping of Plasmodium falciparum infected erythrocytes is associated with high parasitemia but not severe clinical manifestations of malaria in African children. 
  • Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum isolates from Venezuela. 
  • Polymerase chain reaction adjustment in antimalarial trials: molecular malarkey? 
  • Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. 
  • Predicting mortality for paediatric inpatients where malaria is uncommon. 
  • Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection. 
  • Prevalence of Clinical and Subclinical Plasmodium falciparum and Plasmodium vivax Malaria in Two Remote Rural Communities on the Myanmar-China Border. 
  • Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. 
  • Providing lipid-based nutrient supplement during pregnancy does not reduce the risk of maternal P falciparum parasitaemia and reproductive tract infections: a randomised controlled trial. 
  • Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. 
  • Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. 
  • Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? 
  • Quantification of the burden and consequences of pregnancy-associated malaria in the Democratic Republic of the Congo. 
  • Rapid Diagnostic Test Performance Assessed Using Latent Class Analysis for the Diagnosis of Plasmodium falciparum Placental Malaria. 
  • Rapid increases in parasitemia following red cell exchange for malaria. 
  • Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. 
  • Reduced T regulatory cell response during acute Plasmodium falciparum infection in Malian children co-infected with Schistosoma haematobium. 
  • Reduced interleukin-12 and transforming growth factor-beta1 in severe childhood malaria: relationship of cytokine balance with disease severity. 
  • Reduced peripheral PGE2 biosynthesis in Plasmodium falciparum malaria occurs through hemozoin-induced suppression of blood mononuclear cell cyclooxygenase-2 gene expression via an interleukin-10-independent mechanism. 
  • Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. 
  • Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. 
  • Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. 
  • Reply to Harrington et al. 
  • Return of chloroquine antimalarial efficacy in Malawi. 
  • Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. 
  • Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. 
  • Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. 
  • Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. 
  • Safety profile of L-arginine infusion in moderately severe falciparum malaria. 
  • Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes. 
  • Seroreactivity to Plasmodium falciparum erythrocyte membrane protein 1 intracellular domain in malaria-exposed children and adults. 
  • Seroreactivity to a large panel of field-derived Plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 variants reflects seasonal and lifetime acquired responses to malaria. 
  • Serum antibody levels to glycosylphosphatidylinositols in specimens derived from matched Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. 
  • Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. 
  • Shared features in the pathobiology of babesiosis and malaria. 
  • Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. 
  • Sources of variability in determining malaria parasite density by microscopy. 
  • Spatio-temporal analysis of malaria within a transmission season in Bandiagara, Mali. 
  • Spread of artemisinin resistance in Plasmodium falciparum malaria. 
  • Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine. 
  • Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate. 
  • Subclinical Plasmodium falciparum infections act as year-round reservoir for malaria in the hypoendemic Chittagong Hill districts of Bangladesh. 
  • Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. 
  • Suppression of prostaglandin E2 by malaria parasite products and antipyretics promotes overproduction of tumor necrosis factor-alpha: association with the pathogenesis of childhood malarial anemia. 
  • Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. 
  • The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women. 
  • The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. 
  • The diagnosis of Plasmodium falciparum infection using a new antigen detection system. 
  • The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. 
  • The evolution of drug-resistant malaria. 
  • The geography of malaria genetics in the Democratic Republic of Congo: A complex and fragmented landscape. 
  • The influence of individual preventive measures on the clinical severity of malaria among Nigerian children. 
  • The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. 
  • The practice of jhum cultivation and its relationship to Plasmodium falciparum infection in the Chittagong Hill Districts of Bangladesh. 
  • Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. 
  • Trans-kingdom small RNA transfer during host-pathogen interactions: The case of P. falciparum and erythrocytes. 
  • Translocation of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance. 
  • Use of area under the curve to characterize transmission potential after antimalarial treatment. 
  • Vaccine-Resistant Malaria. 
  • Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications. 
  • White blood cell counts and malaria. 
  • [In vitro cultivation of fields isolates of Plasmodium falciparum in Mali] 
  • [LMP-420, a new therapeutic approach for cerebral malaria?]. 
• 

  Keywords of People

  • O'Meara, Wendy P, Associate Professor in Medicine, Medicine, Infectious Diseases